Frontier mental health research: psychedelics & drug studies

Key findings

• Researchers are testing MDMA inside psychotherapy for a range of conditions, and addiction is being studied among those possibilities. ^{15098 15058 15063}
• Most of the strongest clinical evidence for MDMA is for PTSD; the evidence for using MDMA to treat addiction is still limited and preliminary. ^{15063 15091 15058}
• MDMA-assisted therapy can increase feelings of trust, emotional openness, and social connection during sessions, and patients often describe these experiences as important. ^{15091 15092 15063}
• The way MDMA is given matters a lot: careful screening, preparation before the drug session, the therapy during and after, and a safe setting are common parts of studies and are considered important for outcomes. ^{15065 15063 15087}
• Trials done in controlled medical settings have reported generally acceptable safety results so far, but researchers emphasize the need for close monitoring and more safety data over time. ^{15087 15063 15091}
• Experts say it is unclear how much of any clinical benefit comes from MDMA itself versus the intensive therapy, preparation, and the treatment setting that accompany the drug. ^{15087 15092}
• People of color and other minority groups have been underrepresented in psychedelic therapy studies, so we cannot assume trial results apply equally to all populations. ^{15095 15094}
• Important questions still need answers: whether MDMA helps specific types of addiction, how long any benefit lasts, the best safe dose and course for addiction, and the long‑term risks — all need more research. ^{15087 15091 15058}